Pentwater Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Pentwater Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-200,000	Closed	-$4.23M	–	249
2021 Q2	$4.23M	Buy	+200,000	New	+$4.82M	0.03%	110
2020 Q1	–	Sell	-15,000	Closed	-$894K	–	136
2019 Q4	$894K	Sell	15,000 -140,000	-90%	-$6.29M	0.01%	107
2019 Q3	$5.68M	Hold	155,000	–	–	0.09%	64
2019 Q2	$7.21M	Buy	+155,000	New	+$7.28M	0.08%	83
2019 Q1	–	Sell	-183,400	Closed	-$8.44M	–	149
2018 Q4	$8.44M	Buy	+183,400	New	+$8.84M	0.07%	58
2018 Q3	–	Sell	-60,000	Closed	-$2.35M	–	152
2018 Q2	$2.35M	Buy	+60,000	New	+$3.03M	0.02%	81
2018 Q1	–	Sell	-185,000	Closed	-$12.2M	–	98
2017 Q4	$12.2M	Buy	185,000 +5,000	+3%	+$269K	0.08%	61
2017 Q3	$9.02M	Buy	180,000 +140,000	+350%	+$6.75M	0.08%	67
2017 Q2	$1.85M	Sell	40,000 -60,000	-60%	-$2.21M	0.02%	93
2017 Q1	$3.53M	Buy	+100,000	New	+$2.29M	0.04%	70

Other funds holding ESPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Pentwater Capital Management's ESPR Position: Q4 2025 in Review

Pentwater Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 181,290 shares — an estimated $480K sold.

Pentwater Capital Management first reported a position in ESPR in Q3 2013 and held it in 45 quarters. The position peaked at $167M in Q1 2018. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

Pentwater Capital Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
Pentwater Capital Management sold 181,290 Esperion Therapeutics shares in Q4 2025, an estimated $480K.
Pentwater Capital Management first reported a position in Esperion Therapeutics in Q3 2013 and held it in 45 quarters.
Pentwater Capital Management's Esperion Therapeutics position peaked at $167M in Q1 2018.
200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Pentwater Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.